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ABSTRACT
Candida auris is an emerging multidrug-resistant fungal pathogen responsible for nosocomial 
outbreaks of invasive candidiasis. Although several studies on the pathogenicity of this species 
have been reported, the knowledge on C. auris virulence is still limited. This study aims to analyze 
the pathogenicity of C. auris, using one aggregating isolate and eleven non-aggregating isolates 
from different clinical origins (blood, urine and oropharyngeal specimens) in two alternative host 
models of candidiasis: Caenorhabditis elegans and Galleria mellonella. Furthermore, possible 
associations between virulence, aggregation, biofilm-forming capacity, and clinical origin were 
assessed. The aggregating phenotype isolate was less virulent in both in vivo invertebrate 
infection models than non-aggregating isolates but showed higher capacity to form biofilms. 
Blood isolates were significantly more virulent than those isolated from urine and respiratory 
specimens in the G. mellonella model of candidiasis. We conclude that both models of candidiasis 
present pros and cons but prove useful to evaluate the virulence of C. auris in vivo. Both models 
also evidence the heterogeneity in virulence that this species can develop, which may be 
influenced by the aggregative phenotype and clinical origin.
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Candida albicans is the predominant etiological agent of 
invasive candidiasis [1,2]. However, recently Candida auris 
is emerging as a major cause of invasive nosocomial infec-
tions with multidrug-resistance and high morbidity and 
mortality [3,4]. Since this species was first described in 
2009, several clinical presentations, such as colonization, 
mucosal infection or bloodstream infection have been 
reported worldwide, mostly associated with outbreaks in 
surgical and medical intensive care units (ICU) [5,6]. 
Phenotypic and genotypic characterization studies of 
C. auris isolates from different countries have revealed the 
high diversity of this species identifying up to five possible 
different phylogeographical clades, four clearly distinct and 
a potential fifth clade, around the world [6,7].
A wide array of virulence mechanisms is encoded in 
the genome of C. auris [8]. Expression of phospholi-
pase, proteinase, and hemolytic activities, adherence 
and biofilm formation, antifungal drug and environ-
mental stress resistance are described among the most 
relevant virulence traits [9–11]. However, the 
knowledge on C. auris virulence remains scarce and 
further studies are required to understand its patho-
genic behavior, which has been reported to be substan-
tially variable among clades [12]. Currently, about 30 
studies have incorporated in vivo models in the analysis 
of C. auris virulence, murine models being the most 
widely used [13–18]. However, ethical and economical 
issues for using these models of candidiasis are 
encouraging the use of alternative systems such as 
invertebrate models [19,20]. Several virulence studies 
of C. auris infections have been reported in invertebrate 
models using Caenorhabditis elegans, Drosophila mela-
nogaster, Danio rerio or Galleria mellonella [11,21–29]. 
Moreover, non-mammalian hosts have been success-
fully implemented for studying host-pathogen interac-
tions and invasive candidiasis caused by other Candida 
species, and to evaluate the effectiveness of new ther-
apeutic approaches [11,30–33].
Advances in the knowledge of the virulence potential 
of C. auris will contribute to the control of infections by 
this emerging pathogen. Recently, two different 
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phenotypes, aggregating and non-aggregating (single- 
cell phenotype), have been described among C. auris 
clinical isolates; the latter presenting a higher virulence 
[21,22,26]. Transcriptional profiles were evidently dif-
ferent between isolates with these two different pheno-
types, and differences in the host response, depending 
on whether there is loss of tissue integrity, were also 
reported [12]. Although attempts have been made to 
correlate the site of origin of clinical isolates with their 
virulence in different Candida species [34–37], no asso-
ciation has been reported between the pathogenicity of 
C. auris and the origin of clinical specimens.
Therefore, the aim of this study was to analyze the 
virulence of C. auris isolates including both, aggregat-
ing and non-aggregating phenotypes that were 
retrieved from different clinical specimens. The ability 
of several C. auris isolates to form biofilms and produce 
hemolytic and enzymatic activity was assessed in vitro 
and the virulence traits of these isolates were probed 
in vivo using the invertebrate model hosts, C. elegans 
and G. mellonella. Our results demonstrate that both 
model organisms can be killed by aggregative as well as 
non-aggregative C. auris isolates. Moreover, this study 
reaffirmed that the variability among C. auris isolates as 
well as the site of infection and the different immune 
response of the host could affect this species virulence, 
being the C. auris blood isolates the most virulent.
Materials and methods
Candida auris isolates and growth conditions
Twelve clinical C. auris isolates from different patients 
suffering from candidiasis were analyzed (Table 1). 
These isolates included five from blood, five from 
urine, and two from oropharynx. All but one of the 
isolates came from patients of the Hospital 
Universitario y Politécnico La Fe of Valencia, Spain 
(Dr. Alba Ruiz Gaitán and Dr. Javier Pemán), three of 
them being registered in the CBS-KNAW culture col-
lection of Westerdijk Fungal Biodiversity Institute. One 
blood isolate, C. auris JMRC:NRZ 1101 (Jena Microbial 
Resource Collection) was recovered from a patient 
attended at the Institut für Hygiene und 
Mikrobiologie, Würzburg, Germany (Dr. Oliver 
Kurzai).
C. auris isolates were stored in vials containing ster-
ile distilled water at room temperature and cultured on 
Sabouraud dextrose agar (Difco, Becton Dickinson, 
USA) at 37°C for 24 h before use. The assays in the 
C. elegans model were performed by culturing C. auris 
on brain heart infusion (BHI, Panreac, Spain) agar 
plates supplemented with kanamycin (90 µg/ml) and 
incubated at 37°C for 24 h. C. auris isolates used for the 
G. mellonella model assay and for biofilm studies were 
cultured in yeast extract peptone dextrose broth 
(YEPD, Panreac) and incubated overnight at 30°C in 
shaking conditions.
Microscopic visualization
The cellular morphology of the 12 clinical C. auris 
isolates was observed microscopically. C. auris isolates 
were grown in YEPD broth for 24 h at 30°C in shaking 
conditions, washed three times with sterile phosphate- 
buffered saline solution (PBS, Sigma-Aldrich, USA) and 
collected by centrifugation at 2500 rpm for 10 min. Cell 
suspensions of each C. auris isolate were adjusted to 
a final concentration of 1 × 108 cells/ml with sterile PBS 
after cell counting by microscopy using a Burker hemo-
cytometer. Microscopic appearance of each sample was 
visualized using a Nikon Eclipse 80i fluorescence 
microscope (Melville, NY, USA).
Table 1. Biofilm biomass and metabolic activity levels of each C. auris isolate measured with Crystal violet and XTT reduction assays, 
respectively.
Biomass of biofilm Metabolic activity of biofilm
Species Origin site Isolate OD (24 h) OD (48 h) OD (24 h) OD (48 h)
Candida albicans SC5314 0.719 ± 0.066 0.696 ± 0.071 1.159 ± 0.154 1.247 ± 0.172
Candida auris blood JMRC:NRZ 1101* 0.508 ± 0.047 0.361 ± 0.039 0.421 ± 0.147 0.357 ± 0.075
CJ94 0.068 ± 0.038 0.080 ± 0.046 0.145 ± 0.070 0.122 ± 0.031
CBS15605 0.074 ± 0.049 0.079 ± 0.048 0.156 ± 0.086 0.124 ± 0.033
CBS15606 0.068 ± 0.042 0.083 ± 0.051 0.135 ± 0.062 0.103 ± 0.028
CBS15607 0.086 ± 0.079 0.077 ± 0.043 0.132 ± 0.074 0.098 ± 0.023
urine CR14 0.227 ± 0.034 0.179 ± 0.054 0.237 ± 0.095 0.114 ± 0.060
CR201 0.080 ± 0.036 0.057 ± 0.023 0.118 ± 0.035 0.122 ± 0.067
CR220 0.103 ± 0.038 0.062 ± 0.030 0.119 ± 0.020 0.102 ± 0.048
CR424 0.101 ± 0.024 0.082 ± 0.026 0.057 ± 0.039 0.056 ± 0.045
CR440 0.090 ± 0.027 0.074 ± 0.025 0.121 ± 0.033 0.115 ± 0.055
oropharyngeal CR243 0.065 ± 0.033 0.084 ± 0.035 0.146 ± 0.056 0.119 ± 0.042
CR312 0.081 ± 0.024 0.085 ± 0.046 0.085 ± 0.030 0.087 ± 0.047
OD: optical density 
*The C. auris JMRC:NRZ 1101 blood isolate displayed an aggregating phenotype 
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Biofilm development
The ability of C. auris isolates to develop biofilms was 
assessed with C. albicans strain SC5314 being included 
as control. Biofilms were produced in sterile, flat- 
bottomed honeycomb 100-well polystyrene microtiter 
plates (Labsystems, Finland). Precultured cells were 
harvested and washed three times with sterile PBS. 
After cell counting by microscopy, suspensions at 
a concentration of 1 × 106 cells/ml were prepared in 
RPMI 1640 medium supplemented with L-glutamine 
and buffered at pH 7 with 0.165 M 3-(N-morpholine) 
propanesulfonic acid, MOPS (Sigma-Aldrich). 
A volume of 100 µl of each cell suspension was dis-
pensed into the wells of the plate. All outer wells from 
the first and last column of the plate were kept empty 
to avoid the “edge-effect”. Microplates were incubated 
at 37°C for 24 or 48 h. Afterward, to carefully eliminate 
planktonic and poorly adhered cells, spent RPMI was 
removed and the biofilms were washed three times by 
adding and removing 100 µl of sterile PBS.
Quantification of biofilm biomass was performed by 
Crystal violet (CV) staining [38]. After drying the 
washed biofilms at room temperature for 30 min, 
100 µl of 0.4% CV solution (Merck, Germany) was 
added to each well and incubated for 20 min at room 
temperature. Each well was then washed twice with 
250 µl of sterile distilled water, and finally 150 µl of 
33% acetic acid was added to solubilize the CV-stained 
biomass for spectrophotometric measurement.
Biofilm metabolic activity was evaluated by reduc-
tion of 2,3-bis (2-methoxy- 4-nitro-5-sulfophenyl)- 
5-[(phenylamino)-carbonyl]- 2 H-tetrazolium hydro-
xide (XTT, Sigma-Aldrich) [39]. A volume of 100 µl 
of XTT with 1 μM of menadione was added to each 
washed well, and microplates were incubated in dark-
ness for 2 h at 37°C.
Absorbance measurements were conducted with 
a BioScreen C MBR microplate reader (Growth 
Curves Ltd, Finland) at a wavelength of 600 nm for 
biomass quantification and at 492 nm for metabolic 
activity determination. Each experiment was performed 
with biological triplicates on separate days.
Determination of phospholipase, proteinase and 
hemolytic activities
Phospholipase activity was determined using 
a precipitation assay as described by Polak (1992) [40] 
with malt agar plates supplemented with egg yolk [41]. 
Phospholipase activity was defined as the ratio of the 
colony diameter compared to the total diameter of 
colony plus precipitation zone. C. albicans isolate 
UPV/EHU 04–125 was used as a control with high 
phospholipase activity.
Aspartyl proteinase activity was assayed as described 
by Cassone et al. (1987) [42]. Proteinase activity was 
determined as the diameter of the lytic area around 
growing colonies. High aspartyl proteinase producer 
strain Candida dubliniensis UPV/EHU 00–134 was 
used as a control.
Hemolytic activity was analyzed as described by Luo 
et al. (2001) [43] by performing the plate assay 
described by Manns et al. (1994) [44]. C. albicans 
ATCC 90028 with high hemolytic activity was used as 
a control.
Enzymatic and hemolytic activities were analyzed at 
least with biological triplicates on separate days.
Survival assays in Caenorhabditis elegans
C. elegans strain AU37 (glp-4(bn2); sek-1(km4)) was 
obtained from the Caenorhabditis Genetics Center 
(University of Minnesota, USA). The double mutation 
in this strain generates nematodes that are not able to 
reproduce at 25°C (glp-4) and are more susceptible to 
infection (sek-1). The nematodes were kept in the 
laboratory at 15°C in plates with nematode growth 
medium (NGM, 3 g of NaCl, 17 g of agar, 2.5 g of 
peptone, 1 ml of 1 M CaCl2, 1 ml of 5 mg/ml choles-
terol in ethanol, 1 ml of 1 M MgSO4, 25 ml 1 M KPO4, 
975 ml H2O) seeded with the nonpathogenic 
Escherichia coli strain OP50 as nourishment. Prior to 
survival experiments, nematodes were synchronized to 
the same growth stage, as described by Ortega-Riveros 
et al. (2017) [32]. Nematodes were then placed on BHI 
agar plates supplemented with kanamycin (90 µg/ml) 
and seeded with the isolate of C. auris to be assayed to 
feed the nematodes with the yeast [45]. After incubat-
ing the plates at 25°C for 2 h, the nematodes were 
washed with M9 buffer (3 g of KH2PO4, 6 g of Na2 
HPO4, 5 g of NaCl, 1 ml of 1 M Mg SO4 and H2O to 
1 l) supplemented with kanamycin (90 µg/ml) and 
placed in plates with NGM agar for 15 min to elim-
inate, by friction, C. auris cells that might have adhered 
to the nematode cuticle. Nematodes were placed in 
groups of 20 individuals in 24-well plates containing 
M9 buffer supplemented with 10 μg/ml of cholesterol 
in ethanol and kanamycin (90 µg/ml). Nematode sur-
vival was monitored every 24 h until 120 h with 
a stereomicroscope (Nikon SMZ-745, Japan). 
A minimum of 60 nematodes were used in each experi-
ment for each C. auris isolate, and groups of uninfected 
nematodes were included as controls. The experiments 
were carried out in triplicate on different days.
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Survival tests in Galleria mellonella
G. mellonella larvae with a weight between 0.3 and 0.5 g 
were obtained from Bichosa (Spain). Experiments were 
started one day after caterpillars arrived, which were placed 
in groups of 20 individuals in Petri dishes. The last left pro- 
leg of each larvae was cleaned with 70% ethanol and 10 µl of 
a C. auris suspension were inoculated with a precision 
syringe (Agilent, USA). Inoculum of C. auris cells was 
prepared by washing overnight yeast cultures with PBS 
supplemented with ampicillin (20 μg/ml) to remove rem-
nants of YEPD and prevent bacterial contamination. 
Concentrations of 1 × 105, 1 × 106 and 1 × 107 cells/larva 
were assayed to monitor the virulence of each C. auris 
isolate. In all trials, two uninfected groups were used as 
controls; one with untouched larvae and a sham group with 
larvae inoculated with 10 µl PBS-ampicillin to observe 
a possible effect of the injection. Survival counts of alive 
and dead larvae were determined by visual inspection of 
movement and melanization every 24 h until 120 h after 
infection. Trials were conducted in triplicate on three dif-
ferent days.
Statistics
The quantitative results obtained in biofilm produc-
tion were analyzed using the Student’s t test of the 
statistical program SPSS v24.0 (IBM, Chicago, IL, 
USA). The analysis of the virulence of C. auris iso-
lates according to the origin of clinical specimens was 
analyzed by one-way ANOVA using SPSS v24.0. 
Survival curves were prepared with the Kaplan– 
Meier method using GraphPad Prism 5 software 
(GraphPad Software, La Jolla, CA, USA). 
Differences between the survival rates in both inver-
tebrate models infected with C. auris were analyzed 
by the log-rank test of SPSS v24.0. For all statistical 
analyses values of p < 0.05 were considered statisti-
cally significant.
Results and discussion
In the present study, we characterized virulence traits of 12 
clinical isolates of C. auris in vitro and compared their 
capability to infect and kill C. elegans and G. mellonella 
in vivo. These C. auris isolates, that were recovered from 
patients at two different locations (Spain and Germany), 
were observed microscopically, and only the blood isolate 
JMRC:NRZ 1101 from Germany displayed an aggregating 
phenotype, which was not observed in the other C. auris 
isolates from Spain (Figure S1).
Biofilm formation, enzymatic activity, and 
hemolytic activity of Candida auris
The ability of the 12 C. auris clinical isolates to 
develop biofilms is summarized in Table 1. None of 
the 12 isolates produced a biofilm denser than the 
C. albicans SC5314 control strain (Table 1). The 
ability to form a biofilm is an important factor in 
Candida pathogenicity because fungal cells within 
biofilms are protected from the action of the immune 
system and antifungal agents. The lower C. auris 
biofilm production compared to C. albicans SC5314 
has been reported previously [9]. Blood isolate 
JMRC:NRZ 1101 with aggregating phenotype showed 
the highest biofilm biomass production and meta-
bolic activity (p ≤ 0.0001). The non-aggregating 
urine isolate CR14 produced the second most dense 
biofilm with a significantly higher biomass 
(p ≤ 0.0001) and metabolic activity (p ≤ 0.02, except 
at 48 h for most of isolates) than the other C. auris 
isolates. Although C. auris biofilms are thinner than 
those of C. albicans [46], the capacity of C. auris to 
form a biofilm has been clearly associated with 
a lower antifungal susceptibility [16,47]. The ability 
of C. auris to form a biofilm has been reported for 
both aggregating and non-aggregating phenotypes 
[12]. Biomass values obtained in the current study 
were similar to those reported by Sherry et al. (2017) 
[22]. However, these authors reported the highest 
biofilm-forming capacity for non-aggregating isolates. 
Brown and coworkers [12] also detailed differences in 
gene expression between both phenotypes: genes 
related to cellular components (membrane and cell 
wall constituents) were upregulated in isolates with 
aggregating phenotype whereas genes related to bio-
logical processes and metabolic functions were 
expressed higher in non-aggregating isolates. 
Moreover, Short et al. (2019) [48] suggested that 
the ability of C. auris to form cellular aggregates 
increases survival of the yeast, which coincided with 
the upregulation of biofilm-associated genes. In addi-
tion, in C. albicans, the ability to produce biofilm has 
been associated with the expression of secreted aspar-
tyl proteinases [49]. Genes involved in biofilm for-
mation and in the production of phospholipase, 
proteinase and hemolysin activity have been reported 
in C. auris, with genes involved in cell adhesion and 
invasion (ALS and SAP families) showing stronger 
expression in aggregating than in non-aggregating 
isolates [8,12,13,50]. However, in the present study, 
phospholipase and proteinase activities were not 
detected in any clinical isolate nor any hemolytic 
activity was observed (Table S1).
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Virulence of Candida auris in Caenorhabditis 
elegans and Galleria mellonella
C. auris virulence has been studied in murine [13–-
13–15,17,24], fish [28], and fly models [25]. However, 
there have only been a few studies in the nematode 
C. elegans [23,29] and the moth larvae G. mellonella 
[21,22,24,26,27]. In the present study, all C. auris iso-
lates were able to cause the death of at least 47.7% of 
C. elegans and G. mellonella individuals after 120 
h (Figure 1).
Uninfected C. elegans nematodes used as controls 
remained viable (100% survival) during the 120 h. 
A high amount of non-aggregating yeast cells was 
observed at 120 h post-infection for all C. auris isolates, 
except for the C. auris JMRC:NRZ 1101 isolate that 
caused yeast aggregates at 120 h post-infection in 
C. elegans (Figure S2). This cellular pattern was also 
observed in infected G. mellonella (data not shown). 
These results are consistent with those reported by 
Borman et al. (2016) [21] who first described the for-
mation of aggregates by some C. auris isolates, which 
later was corroborated by Sherry et al. (2017) [22] and 
Muñoz et al. (2020) [11]. These studies reported that 
C. auris did not form hyphae unlike C. albicans in the 
G. mellonella model of candidiasis, and that non- 
aggregating C. auris isolates were more virulent, even 
when compared to some C. albicans isolates [11,21,22]. 
In a murine model, Ben-Ami et al. (2017) [13] also 
identified yeast cells during the infection and recovered 
aggregates from murine tissues. Yue et al. (2018) [15] 
observed a filamentous morphology of C. auris in cul-
tures on YEPD medium from liver, kidney, brain, lung, 
and spleen specimens of mice suffering from invasive 



















































Figure 1. Survival average of C. elegans (a) and G. mellonella (b) at 120 hours post-infection with twelve different C. auris isolates 
according to the origin of the clinical specimen. Untouched control groups of nematodes and larvae and a group of larvae 
inoculated with PBS and ampicillin were also included. Larvae of G. mellonella were infected with three inocula of C. auris isolates 
(1 × 105, 1 × 106 and 1 × 107 cells/larva) and correlation coefficients were calculated. Absent bars indicate 0% survival rate of 
G. mellonella. Error bars represent standard errors. Solid lines with asterisks denote statistically significant differences of the inoculum 
1 × 105 cells/larva between C. auris blood isolates and the other C. auris isolates from urine and oropharyngeal. Dotted lines with 
hashtag denote statistically significant differences of the inoculum 1 × 106 cells/larva between C. auris blood isolates, without 
including the aggregative German isolate, and the other C. auris isolates from urine and oropharyngeal. The statistical analysis was 
performed using the one-way ANOVA test (p < 0.05).
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followed by five additional days at 25 °C were needed to 
observe this morphological switch from yeast to 
hyphae.
Killing assays in G. mellonella were performed with 
inocula of 1 × 105, 1 × 106 and 1 × 107 cells/larva for 
each C. auris isolate. In both control groups, most 
larvae were alive by 120 h post-infection with survival 
averages of 85% ± 3.2% in the case of the untouched 
group control and 82.3% ± 3.6% in larvae inoculated 
with PBS-ampicillin (Figure 1). Survival of 
G. mellonella significantly decreased when a higher 
inoculum of C. auris was administered, as reported 
for other species of Candida [31,51,52]. There was 
a strong correlation (R2 ≥ 0.87) between the injected 
inocula of C. auris and the survival of G. mellonella. 
Interestingly, there were statistically significant differ-
ences between the virulence of C. auris blood isolates 
and that of urine and oropharyngeal isolates using the 
inoculum of 1 × 105 cells/larva (p ≤ 0.009). Differences 
were also detected with the inoculum of 1 × 106 cells/ 
larva without considering the isolate with aggregating 
phenotype (p ≤ 0.032) (Figure 1). The inoculum of 
1 × 106 cells/larva appeared the most appropriate for 
analyzing the virulence of C. auris in the G. mellonella 
model based on the findings with all the C. auris iso-
lates at the three different inocula and the mortality 
rates obtained. Therefore, the results obtained with 
1 × 106 cells/larva are presented and discussed in detail 
in the main text while those obtained with other 
inocula are presented in Figure S3. Inocula of 1 × 107 
cells/larva caused the death of more than 60% of the 
larvae during the first 24 h of infection, and of more 
than 98.3% at 120 h (Figure S3). On the opposite, with 
the lowest inoculum of 1 × 105 cells/larva, none of the 
C. auris isolates had killed more than 60% of 
G. mellonella larvae at 48 h, with mortality ranging 
from 43.7% to 83.3% at 120 h (Figure S3). In this in vivo 
model the highest mortality was observed for blood 
isolates (Figure 1).
Virulence of C. auris isolates according to the origin 
of the clinical specimens
Differences in the expression of virulence factors have 
been observed between C. auris isolates from different 
geographical origins, such as the lack of adhesion or 
few biofilm production associated with clade II isolates 
(East Asian clade), which frequently cause otitis 
[12,53,54]. Several studies have associated the expres-
sion of specific virulence factors of Candida with the 
site of infection [34–37]. In the present study, C. auris 
isolates were not grouped within any specific clade but 
the eleven isolates from the Spanish outbreak are phy-
logenetically close to clade III isolates (South African 
clade) [5,6]. This clade III, as well as clade II, is asso-
ciated with bloodstream infections and with aggregate 
formation [55].
We compared the virulence of the C. auris isolates 
according to their clinical origin in both in vivo 
models. The applied inoculum size of 1 × 106 cells/ 
larva or lower (2.5–5 × 105 cells/larva) has also pre-
viously been used to establish the virulence of 
C. auris [21,22,24,26,27] and other species of 
Candida [30,51,52]. Strikingly, the C. auris isolates 
presented different virulence potential according to 
their clinical origin. In the G. mellonella model, the 
following general virulence categorization was 
observed when comparing the eleven non- 
aggregating isolates: blood > urine > oropharyngeal 
isolates with average survival percentages of infected 
larvae after 120 h of 1.7% for blood, 7.5% for urine, 
and 12.5% for oropharyngeal isolates. In contrast, 
mortality of C. elegans caused by infection with 
C. auris isolates was not clearly associated to their 
clinical origin. The average survival of nematodes 
infected with the non-aggregating C. auris isolates 
was very similar for the three groups of clinical iso-
lates: 13.6% for the infection with blood isolates, 
11.8% with urine isolates, and 10.6% with orophar-
yngeal isolates (Figure 1).
The virulence of the five individual blood isolates, 
the five urine isolates and the two oropharyngeal iso-
lates is presented in Figures 2, 3 and 4, respectively. 
The survival rates of G. mellonella infected with blood 
isolates ranged from 0% to 10% at 120 h, and from 
7.6% to 52.3% in the C. elegans model. Moreover, most 
of the C. auris isolates killed more than 70% of the 
G. mellonella larvae at 24 h but took more than 96 h in 
the C. elegans model (Figure 2). Survival rates for 
G. mellonella infected with urine isolates were between 
1.7% and 18.3% at 120 h (7.8–17.2% in C. elegans). 
However, all urine isolates killed more than 50% of 
the G. mellonella larvae at 48 h, while in the case of 
C. elegans at least 96 h were required (Figure 3). 
Finally, for the two oropharyngeal isolates there were 
no significant differences in virulence between the two 
non-mammalian models: survival rates of 
G. mellonella at 120 h ranged from 6.7% to 18.3%, 
whereas those of C. elegans were between 10% and 
11.2%. Once again, in G. mellonella both isolates killed 
more than 60% of the larvae after 48 h but in C. elegans 
they took 96 h to eliminate the same percentage of host 
organisms (Figure 4). In all cases, in the first 24–48 h 
post-infection C. auris caused higher mortality in the 
G. mellonella model than in the C. elegans model 
(Figures 2–4). These results are comparable to those 
obtained in other studies, which observed that C. auris 
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caused death of G. mellonella within 48 h [21,22] and 
of C. elegans between 48 and 96 h post-infection 
[23,29]. Our findings corroborate the idea that both 
models successfully demonstrate the virulence poten-
tial of C. auris, which was similar to or higher than that 
of other Candida species [11,30,32,33,52]. The 
observed virulence of C. auris was comparable to 
C. albicans [21,22,29] and higher than isolates from 
C. haemulonii complex species [11,29]. However, also 
within the species C. auris differences in virulence 
between isolates from different clades have been 
noted, probably associated with their genomic diver-
sity [12].
The C. auris JMRC:NRZ 1101 blood isolate, with 
aggregating phenotype, was significantly less viru-
lent than the other blood isolates in both models 
(p ≤ 0.0001) (Table S2 and S3). This isolate killed 
more than 80% of the G. mellonella larvae in 96 h, 
but it took 120 h to achieve a mortality rate of 
52.3% of C. elegans nematodes (Figure 2). 
Association of an aggregative phenotype of C. auris 
with lower pathogenicity compared to non- 
aggregating counterparts has also already been 
described earlier [21,22]. Furthermore, the virulence 
of this aggregating isolate in C. elegans was also 
significantly lower than that of all non-aggregating 
isolates from different infection sites (p ≤ 0.0001) 
(Figures 3 and 4; Table S3). In G. mellonella, the 
aggregating isolate caused a mortality comparable to 
that of most isolates from other clinical origins 
(Figure 2 and Table S2) and only the mortality 
caused by this isolate was significantly lower than 
of urine isolate CR201 (p = 0.016).
Regarding non-aggregating C. auris isolates, blood 
isolate CBS15607 killed 100% of G. mellonella at 120 h 
but no significant differences were observed with other 
non-aggregating blood isolates (Figure 2). High viru-
lence was observed for four out of five urine isolates 
(80%), which killed G. mellonella with a mortality rate 
ranging from 80% to 93.3% between 72 and 120 h 
without significant differences among them (Figure 3). 
The CR312 oropharyngeal isolate also killed 93.3% of 
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Figure 2. Survival curves of G. mellonella (a) and C. elegans (b) infected with C. auris blood isolates. Larvae of G. mellonella were 
infected with 1 × 106 cells/larva and the control groups used were a group of untouched larvae and larvae inoculated with PBS and 
ampicillin (PBS+amp) as a puncture (sham) control group. C. elegans worms were infected by C. auris cell ingestion for 2 h. c) 
Survival percentages at 120 h post-infection of G. mellonella and C. elegans infected with C. auris blood isolates. The C. auris isolates 
were sorted from highest to lowest survival percentages of C. elegans. Statistically significant differences in pathogenicity of C. auris 
blood isolates compared to the least virulent isolate JMRC:NRZ 1101 (* C. elegans; ** G. mellonella) and the second least virulent 
isolate CJ94 (#) calculated using the log-rank test (p < 0.05) are indicated. Absent bars indicate 0% survival rate.
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larvae at 120 h (Figure 4); however, its killing kinetics 
were similar to the two isolates with the lowest viru-
lence, urine isolate CR14 and oropharyngeal isolate 
CR243, which achieved 81.7% mortality at 120 h. 
Conversely, there were significant differences between 
the latter two isolates and the aforementioned four 
urine isolates (p ≤ 0.006 and p ≤ 0.045, respectively). 
A higher virulence of Candida isolates from blood 
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Figure 3. Survival curves of G. mellonella (a) and C. elegans (b) infected with C. auris urine isolates. Larvae of G. mellonella were 
infected with 1 × 106 cells/larva and the control groups used were a group of untouched larvae and larvae inoculated with PBS and 
ampicillin (PBS+amp) as a puncture (sham) control group. C. elegans worms were infected by C. auris cell ingestion for 2 h. c) 
Survival percentages at 120 hours post-infection of G. mellonella and C. elegans infected with C. auris urine isolates. The C. auris 
isolates were sorted from highest to lowest survival percentages of C. elegans. Statistically significant differences in pathogenicity of 
C. auris urine isolates compared to the least virulent isolate in G. mellonella, C. auris CR14 (*), and the highest virulent isolate in 
C. elegans, C. auris CR424 (#), calculated using the log-rank test (p < 0.05) are indicated.
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specimens has previously been reported [35–37]. 
C. elegans infection by non-aggregating isolates caused 
a mortality rate of more than 76.6% at 120 h and 
C. auris isolates took more than 72 h to exceed a mor-
tality of 50% (Figures 2–4). Eldesouky et al. (2018) [23] 
employed 30 min in the infection of worms and 
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Figure 4. Survival curves of G. mellonella (a) and C. elegans (b) infected with C. auris oropharyngeal isolates. Larvae of G. mellonella 
were infected with 1 × 106 cells/larva and the control groups used were a group of untouched larvae and larvae inoculated with PBS 
and ampicillin (PBS+amp) as a puncture (sham) control group. C. elegans worms were infected by C. auris cell ingestion for 2 h. c) 
Survival percentages at 120 hours post-infection of G. mellonella and C. elegans infected with C. auris oropharyngeal isolates. The 
C. auris isolates were sorted from highest to lowest survival percentages of C. elegans.
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reported similar killing kinetics, whereas Lima et al. 
(2020) [29] infected C. elegans for four hours and 
detected a mortality rate of more than 70% at 72 h. 
Blood isolate CBS15605 and urine isolate CR220 killed 
the highest percentage of nematodes at 120 h, 92.7% 
and 92.2%, respectively. However, no significant viru-
lence differences were observed among them and the 
CBS15606 blood isolate and two urine isolates (CR440 
and CR14) (Table S3). Five out of eleven isolates 
(45.5%) showed the same killing kinetics. Moreover, 
the oropharyngeal isolates also showed high lethality, 
causing a mortality rate of 88.8% at 120 h without 
significant differences with the mortality caused by 
the CBS15607 blood isolate. Strikingly, the less virulent 
isolates in the C. elegans model were the CJ94 blood 
isolate and the CR424 urine isolate with similar killing 
kinetics, both being significantly different to the rest of 
the isolates (Table S3). However, both isolates were 
among the five most virulent against G. mellonella, 
and their mortality rates in the C. elegans and 
G. mellonella models differed: 82.8% versus 98.3% for 
the blood isolate and 76.6% versus 96.7% for the urine 
isolate, respectively.
It is noteworthy that non-aggregating isolates were 
more pathogenic than the aggregating isolate and that 
the aggregating isolate used in this study formed more 
biofilm than the non-aggregating isolates. Sherry et al. 
(2017) [22] reported the opposite, a higher biofilm 
formation capacity in non-aggregating than in aggre-
gating isolates. The aggregating C. auris JMRC:NRZ 
1101 blood isolate could be expressing genes implicated 
in biofilm formation and also genes involved with other 
virulence factors. The expression of these virulence 
genes could render a virulence of this isolate similar 
to that of some non-aggregating isolates, yielding simi-
lar killing kinetics during infection of G. mellonella. 
Transcriptional analysis of C. auris isolates revealed 
a high number of upregulated genes involved in biofilm 
formation and other pathogenic traits, which can be 
associated with the high resistance of this species to 
antifungal drugs [10,12]. In addition, differences in the 
infection profile and the host response to infection were 
observed for aggregating and non-aggregating pheno-
types using a three-dimensional skin epithelial model. 
Although both phenotypes were more virulent in the 
presence of a wound, an aggregating isolate was more 
cytotoxic and proinflammatory than a non-aggregating 
one with more ability to evade the immune system [12]. 
Trying to explain the differences found between both 
models of candidiasis, it is important to mention that in 
G. mellonella C. auris inoculum was injected parenter-
ally, achieving higher concentrations in the tissues. 
Moreover, a higher lethal capacity of the non- 
aggregating isolates versus the aggregating isolate was 
noted in this model, likely due to the differential 
immune response of the host. Arias et al. (2020) [26] 
suggested that, due to a higher ability to move and 
disseminate within G. mellonella tissues, yeast cells 
might be more virulent than aggregates of cells, with 
which we concur. In addition, C. elegans infection 
occurs by yeast ingestion during a defined time. 
Variations in exposure time consequently might result 
in a higher or lower fungal burden, leading to varia-
tions in the killing kinetics [32]. It may also be possible 
that C. elegans has greater difficulty in ingesting cellular 
aggregates than individual yeasts. This fact could lead 
to a lower intake of fungal burden resulting in a milder 
infection rather than an aggregating isolate being less 
virulent. A stronger cytokine response and lower 
macrophage lysis capacity and neutrophil recruitment 
have been reported for C. auris compared to C. albicans 
[18,28]. Interestingly, structurally unique C. auris man-
noproteins contribute to a strong innate host defense in 
all five C. auris clades, although clade-specific differ-
ences were observed, clade V being the least immuno-
genic [28]. Both infection models, C. elegans and 
G. mellonella, present mechanisms and responses of 
the innate immune system that are conserved in mam-
mals and may contribute to a better understanding of 
host-C. auris interactions.
Overall, in both models, isolates of C. auris behaved 
differently depending on their clinical origin, although 
the response to C. auris infection of the two models of 
candidiasis was also different. These differences in the 
virulence of C. auris according to the site of infection 
seem consistent with reports about the phenotypic plas-
ticity of this species of Candida in response to environ-
mental conditions, such as the passage through 
a mammalian body and variations in temperature to 
colonize a specific niche [15]. However, further studies 
are required using other C. auris isolates with aggregating 
phenotype, if possible, from different geographic clades, 
to assess more accurately their virulence in vivo. There 
may be a level of heterogeneity in virulence among 
aggregating C. auris isolates similar to that observed for 
non-aggregating isolates in this and other studies [12,18].
In conclusion, we demonstrated that both C. elegans 
and G. mellonella models of candidiasis are simple and 
clearly appropriate to assess the virulence of C. auris 
isolates. Likewise, these models are useful to detect 
variations in the virulence of clinical isolates with dif-
ferent origin and/or capacity to form cell aggregates. 
The model host G. mellonella, which allows a more 
precise and direct inoculation of the pathogen into 
the host tissues, revealed a significantly higher virulence 
for C. auris isolates from blood specimens. Among the 
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successful strategies of C. auris to cause infection are its 
ability to evade neutrophil attack and to resist treat-
ments with commonly used antifungal drugs. 
Therefore, obtaining a more effective and accurate ther-
apy is one of the main targets on which to focus actions 
against this pathogen. These low-cost and manageable 
in vivo models are promising tools to analyze host- 
pathogen interactions or the effectiveness of current 
and new antifungal drugs against C. auris.
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